Hims & Hers co-founder and CEO Andrew Dudum said the company will pivot and focus on different offerings such as its oral-based weight loss medications.
If the CMS rule to cover obesity medications is finalized, coverage will increase by other insurers, experts predicted. HHS candidate RFK Jr told senators the GLP-1s are ‘miracle drugs’ but shouldn’t be prescribed for 6-year-olds.
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and Prevention (CDC)[1]. With this statistic in mind, it’s no surprise that many people are curious about Ozempic,
Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.
The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in stand-alone drug plans in recent years.
Makers of copycat weight-loss drugs and digital health companies that sell them are bracing for upheaval now that the Food and Drug Administration has declared Novo Nordisk's blockbusters Ozempic and Wegovy are no longer in shortage.
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Semaglutide was tied to a small risk of nonarteritic anterior ischemic optic neuropathy (NAION) in adults with type 2 ...